Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces safety hurdles
NegativeFinancial Markets

Sarepta Therapeutics, a leader in gene therapy, is currently facing significant safety hurdles that could impact its future. This situation is crucial as it not only affects the company's reputation but also raises concerns about the safety and efficacy of gene therapies in general. Investors and patients alike are watching closely, as the outcomes of these challenges could shape the landscape of genetic medicine.
— Curated by the World Pulse Now AI Editorial System